New bladder cancer drug shows promise in early trial
NCT ID NCT07222488
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests a new medicine called MK-3120 for people with high-risk bladder cancer that hasn't spread to the muscle. After standard surgery to remove the tumor, participants receive MK-3120 directly into the bladder. The main goals are to check safety and side effects, and to see if the drug can eliminate remaining cancer. About 45 adults are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Akershus Universitetssykehus ( Site 0091)
RECRUITINGLorenskog, Akershus, 1478, Norway
Contact Phone: •••-•••-••••
-
Ankara University Health Practice and Research Hospitals ( Site 0132)
RECRUITINGAnkara, 06620, Turkey (Türkiye)
Contact Phone: •••-•••-••••
-
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)
RECRUITINGQuébec, Quebec, G1J 1Z4, Canada
Contact Phone: •••-•••-••••
-
Carolina Urologic Research Center ( Site 0006)
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-••••
-
Centro Ricerche Cliniche di Verona ( Site 0072)
RECRUITINGVerona, Veneto, 37134, Italy
Contact Phone: •••-•••-••••
-
European Interbalkan Medical Center ( Site 0051)
RECRUITINGThessaloniki, 570 01, Greece
Contact Phone: •••-•••-••••
-
Gustave Roussy ( Site 0041)
RECRUITINGVillejuif, Val-de-Marne, 94800, France
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0112)
RECRUITINGMadrid, Madrid, Comunidad de, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Virgen de la Victoria ( Site 0111)
RECRUITINGMálaga, Andalusia, 29010, Spain
Contact Phone: •••-•••-••••
-
Medizinische Universität Wien ( Site 0021)
RECRUITINGVienna, State of Vienna, 1090, Austria
Contact Phone: •••-•••-••••
-
Michael G Oefelein Clinical Trials ( Site 0005)
RECRUITINGBakersfield, California, 93301, United States
Contact Phone: •••-•••-••••
-
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 0062)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
UZ Gent ( Site 0031)
RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.